ストックスクリーナーアプリを入手
2.22
1.33%
-0.03
前日終値:
$2.25
開ける：
$2.25
24時間の取引高:
2.30M
Relative Volume:
0.73
時価総額：
$986.12M
収益：
$69.64M
当期純損益:
$-26.09M
株価収益率:
-31.05
EPS:
-0.0715
ネットキャッシュフロー:
$-38.80M
1週間 パフォーマンス:
-4.31%
1か月 パフォーマンス:
+18.09%
6か月 パフォーマンス:
+89.74%
1年 パフォーマンス:
+96.46%
1日の値動き範囲:
$2.14
$2.25
1週間の範囲:
$2.14
$2.435
52週間の値動き範囲:
$1.00
$2.68
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
名前
Lexicon Pharmaceuticals Inc
セクター
電話
(281) 863-3000
住所
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
2.22 | 986.12M | 69.64M | -26.09M | -38.80M | -0.0715 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-05 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-06-17 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-30 | 開始されました | Leerink Partners | Outperform |
| 2023-03-07 | 開始されました | Jefferies | Hold |
| 2022-08-12 | 開始されました | Piper Sandler | Overweight |
| 2021-01-29 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-01-29 | ダウングレード | Wedbush | Outperform → Neutral |
| 2020-12-08 | アップグレード | Citigroup | Neutral → Buy |
| 2020-11-18 | アップグレード | Gabelli & Co | Hold → Buy |
| 2019-12-11 | ダウングレード | Gabelli & Co | Buy → Hold |
| 2019-11-08 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-09-11 | アップグレード | Gabelli & Co | Hold → Buy |
| 2019-07-29 | ダウングレード | Stifel | Buy → Hold |
| 2019-03-25 | アップグレード | Gabelli & Co | Sell → Hold |
| 2018-07-31 | 繰り返されました | Stifel | Buy |
| 2018-02-23 | ダウングレード | Needham | Buy → Hold |
| 2018-02-14 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2017-03-01 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-03-01 | 繰り返されました | Wedbush | Outperform |
| 2016-10-07 | 開始されました | H.C. Wainwright | Buy |
| 2016-08-05 | 繰り返されました | Wedbush | Outperform |
| 2016-08-02 | 開始されました | Citigroup | Buy |
| 2016-03-02 | 繰り返されました | Wedbush | Outperform |
| 2015-11-09 | 繰り返されました | Wedbush | Outperform |
| 2015-09-28 | アップグレード | Gabelli & Co | Sell → Hold |
| 2015-09-18 | ダウングレード | Gabelli & Co | Hold → Sell |
| 2015-08-10 | ダウングレード | JP Morgan | Overweight → Neutral |
すべてを表示
Lexicon Pharmaceuticals Inc (LXRX) 最新ニュース
What Lexicon Pharmaceuticals (LXRX)'s Broad Russell Index Inclusion Means For Shareholders - simplywall.st
Lexicon Pharmaceuticals outlines its path in gastrointestinal disease. Drug pipeline and Nasdaq list - ad-hoc-news.de
Lexicon Pharmaceuticals (NASDAQ:LXRX) Scores Perfect 10 Technical Rating After 119% Rally - ChartMill
Lexicon Pharmaceuticals highlights diabetes drug focus. Strategy matters more than near-term headlin - ad-hoc-news.de
LXRX News | LEXICON PHARMACEUTICALS INC (NASDAQ:LXRX) - ChartMill
Earnings call transcript: Lexicon Pharmaceuticals Q1 2026 sees dramatic revenue surge - Investing.com
Lexicon Pharmaceuticals (LXRX) Gains on Russell 3000 Inclusion - Yahoo Finance
How Lexicon Pharma’s Expanded Russell Index Footprint Shapes Its Pipeline Narrative for Investors (LXRX) - simplywall.st
Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Lexicon Pharmaceuticals, Inc.(NasdaqCM: LXRX) added to Russell 2000 Index - marketscreener.com
Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 2500 Growth Benchmark - marketscreener.com
Here's why you should add LXRX stock to your portfolio now - MSN
Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 2000 Growth Benchmark - marketscreener.com
Lexicon Pharmaceuticals, Inc.(NasdaqCM: LXRX) added to Russell 3000E Index - marketscreener.com
Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 3000E Growth Benchmark - marketscreener.com
Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 3000 Growth Benchmark - marketscreener.com
LXRX Surges As Traders Pounce On Strong Breakout - StocksToTrade
LXRX Jumps As Traders Focus On Breakout Momentum - timothysykes.com
LXRX Stock Climbs As Bullish Momentum Attracts Short-Term Traders - StocksToTrade
LXRX Climbs As Bulls Press Multi-Day Breakout - timothysykes.com
Lexicon Pharmaceuticals stock hits 52-week high at $2.53 By Investing.com - Investing.com Nigeria
Lexicon Pharmaceuticals stock hits 52-week high at $2.53 - Investing.com UK
Lexicon Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:LXRX) - TradingView
LXRX Forecast — Price Target — Prediction for 2027 - TradingView
Lexicon Pharmaceuticals debuts HCM education booth at heart failure conference - Traders Union
Lexicon Pharmaceuticals Inc (LXRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Here's Why You Should Add LXRX Stock to Your Portfolio Now - TradingView
Lexicon Pharmaceuticals Surges 7%: Technical Breakout in Sight?Volume Breadth - dars.gov.et
Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
Lexicon Pharmaceuticals StockSunday background on strategy and trials - AD HOC NEWS
LEXICON PHARMACEUTICALS INC (LXRX) Stock Chart - ChartMill
Lexicon Pharmaceuticals Inc (LXRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lexicon Pharmaceuticals Inc (LXRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lexicon Pharmaceuticals Inc (LXRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lexicon Pharmaceuticals Inc (LXRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lexicon Pharmaceuticals Inc (LXRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lexicon Pharmaceuticals Inc (LXRX) Institutional Confidence - TradingKey
Lexicon Pharmaceuticals Inc - TradingKey
Lexicon Pharmaceuticals Inc (LXRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Peripheral Neuropathic Pain Market Positioned for Significant Commercial Growth by 2034 – DelveInsight | Grünenthal and Averitas Pharma, Scilex Pharma, Apurano Pharma, Lexicon Pharma, Helixmith - Barchart.com
Lexicon Pharmaceuticals (LXRX) reports break-even earnings for Q1 - MSN
Is Lexicon Pharmaceuticals, Inc. (LXRX) A Good Stock To Buy Now? - Insider Monkey
Lexicon Pharmaceuticals vs Pfizer: Comparing a Small Biotech with a Global DrugmakerNews and Statistics - IndexBox
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026? - Yahoo Finance
Lexicon Pharmaceuticals (LXRX) director converts 89,312 RSUs into common stock holdings - Stock Titan
Diane E. Sullivan converts 89,312 RSUs at Lexicon Pharmaceuticals (LXRX) - Stock Titan
[Form 4] LEXICON PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Lexicon Pharmaceuticals (LXRX) director exercises 89,312 RSUs into shares - Stock Titan
Lexicon Pharmaceuticals (LXRX) director converts 89,312 RSUs into 213,771-share stake - Stock Titan
Lexicon (NASDAQ: LXRX) director converts 89,312 restricted stock units into common stock - Stock Titan
Lexicon (NASDAQ: LXRX) director converts 89,312 RSUs into common stock, boosts stake - Stock Titan
Lexicon Pharmaceuticals Inc (LXRX) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):